Results 1 to 10 of about 6,574,107 (210)

Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR–ABL tyrosine kinase, CGP 57148 [PDF]

Cell Death and Differentiation, 1998
The BCR - ABL tyrosine kinase has been implicated as the cause of Philadelphia chromosome (Ph1)-positive leukemias. We report herein that CGP 57148, a selective inhibitor of the ABL tyrosine kinase, caused apoptosis specifically in bcr - abl-positive chronic myelogenous leukemia (CML) cells, K562 and KYO-1.
Shingo Dan, T Tsuruo
exaly   +3 more sources

Langerhans Cell Histiocytosis Associated With Chronic Myeloid Leukemia: A Pediatric Case Report. [PDF]

Cancer Rep (Hoboken)
ABSTRACT Background Langerhans cell histiocytosis (LCH) is a rare clonal neoplasm driven by activating mutations in the MAPK pathway, leading to accumulation of pathological Langerhans cells in various tissues. LCH is increasingly associated with secondary malignancies, including leukemias, lymphomas, and solid tumors. However, chronic myeloid leukemia
Latifi A, Yousefian S.
europepmc   +2 more sources

Anaphylactic transfusion reaction to group B platelets related to alpha-gal syndrome: A case report. [PDF]

Transfusion
Abstract Background Alpha‐gal syndrome (AGS), a distinct form of IgE‐mediated hypersensitivity to the carbohydrate galactose‐α‐1,3‐galactose (α‐Gal), typically occurs after repeated tick bites and leads to allergic reactions after ingestion of mammalian meat.
Hinojosa OA, Dasgupta A, Ye Z.
europepmc   +2 more sources

One Target, Different Results: The Clinical Impact of Diagnostic Kit Choice in BCR::ABL1 Testing for Chronic Myeloid Leukemia [PDF]

Diagnostics
Background: Quantitative PCR measurement of BCR::ABL1 is essential for monitoring molecular response and detecting relapse in chronic myeloid leukemia (CML) patients.
Mirjana Suver Stević, Vlatka Periša, Karla Vujičić, Saška Marczi, Jasminka Sinčić-Petričević, Danijela Mjeda   +5 more
doaj   +2 more sources

Dual Proteasome and Histone Deacetylase Inhibition Overcomes Tyrosine Kinase Inhibitor Resistance in Breakpoint Cluster Region: Abelson 1-Driven Leukaemia Cell Lines. [PDF]

J Cell Mol Med
ABSTRACT Resistance to tyrosine kinase inhibitors (TKIs) remains a major challenge in breakpoint cluster region (BCR)::Abelson 1 (ABL1)‐driven leukaemias. Asciminib offers a novel therapeutic option; however, resistance continues to emerge. We hypothesised that targeting proteostasis and epigenetic regulation with bortezomib and panobinostat could ...
Okabe S, Yoshizawa S, Arai Y, Gotoh A, Akahane D.   +4 more
europepmc   +2 more sources

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Blood, 2007
Abstract Nilotinib, an orally bioavailable, selective Bcr-Abl tyrosine kinase inhibitor, is 30-fold more potent than imatinib in pre-clinical models, and overcomes most imatinib resistant BCR-ABL mutations. In this phase 2 open-label study, 400 mg nilotinib was administered orally twice daily to 280 patients with Philadelphia chromosome ...
Kapil Bhalla, Francesca Palandri, Hagop Kantarjian   +2 more
exaly   +5 more sources

Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia

Haematologica, 2000
BACKGROUND AND OBJECTIVE: Although bcr-abl polymerase chain reaction (PCR) positivity after bone marrow transplantation (BMT) for chronic myelogenous leukemia (CML) is significantly related to relapse, the predictive value of the assay is not very high ...
J Roman, J Serrano, A Jimenez, JA Castillejo, ML Reina, MG Gonzalez, MC Rodriguez, I Garcia, J Sanchez, J Maldonado, A Torres   +10 more
doaj   +2 more sources

BCR-ABL rearrangements in children with Philadelphia chromosome- positive chronic myelogenous leukemia [PDF]

Blood, 1991
Abstract Leukemia cells from adults with Philadelphia (Ph1)-chromosome positive chronic myelogenous leukemia (CML) have a characteristic molecular rearrangement between the BCR and ABL genes whereby major breakpoint cluster region (Mbcr) exons 2 or 3 are joined to ABL exon II.
I, Aurer, A, Butturini, R P, Gale
openaire   +3 more sources

New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia [PDF]

Blood, 1990
A new and rare type of Bcr/Abl junction between exon C3 of the 3′ portion of the Bcr gene and Abl exon 2 has been identified in the leukemic cells of two Ph1-positive chronic myelogenous leukemia patients in chronic phase. This is the fourth type of Bcr/Abl junction so far identified in Ph1-positive hematologic malignancies and is a consequence of an ...
SAGLIO, Giuseppe, GUERRASIO, Angelo, ROSSO C, ZACCARIA A, TASSINARI A, SERRA, Anna, REGE CAMBRIN G, MAZZA U, GAVOSTO F.   +8 more
openaire   +4 more sources

Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemia.

PLoS ONE, 2022
Chronic myelogenous leukemia (CML) is a hematopoietic stem cell malignancy that accounts for 15-20% of all cases of leukemia. CML is caused by a translocation between chromosomes 9 and 22 which creates an abnormal fusion gene, BCR::ABL1.
Dawne N Shelton, Prasanthi Bhagavatula, Nathan Sepulveda, Lan Beppu, Shital Gandhi, Dahui Qin, Scott Hauenstein, Jerald Radich   +7 more
doaj   +2 more sources